Valencia Technologies

Executive Summary

Valencia Technologies is a private neuromodulation company revolutionizing the treatment of bladder dysfunction with its eCoin® implant, a tibial nerve stimulator for urge urinary incontinence (UUI). Approved and commercially available, eCoin offers a minimally invasive, long-term solution that addresses a significant unmet need: over 30 million Americans suffer from UUI, yet current therapies (medication, sacral neuromodulation, or PTNS) have adherence or invasiveness issues. eCoin’s unique design as a permanent, coin-sized implant provides sustained efficacy with a single procedure, potentially disrupting the standard of care. The company holds a strong position in the medical device market, with FDA approval for UUI and early commercial traction. Its focus on neuromodulation aligns with the growing preference for non-pharmacological interventions. While financial details are undisclosed, the company’s approval stage and niche focus (bladder control) make it an attractive target for strategic acquisitions or partnerships within the urology landscape. Key risks include competition from Axonics, Medtronic, and newer entrants, as well as the need for robust reimbursement and adoption among urologists. Overall, Valencia Technologies is poised for growth, with upcoming milestones likely to include label expansion, real-world evidence, and commercial partnerships.

Upcoming Catalysts (preview)

• 2027FDA Approval for Additional Indications (e.g., Fecal Incontinence or Overactive Bladder)60% success
• Q2 2026Positive Real-World Data or Clinical Study Results Demonstrating Long-Term Efficacy70% success
• 2026Strategic Partnership or Acquisition by Larger MedTech Company50% success